Industry Audit and Company of The year.
2009/03/13
Astellas to Nominate Two Directors to CV Therapeutics Board
Astellas’s hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board
members and replace them with their own.
Grim Outlook For UK Biotech Industry
It could be the end of the road for the UK’s biotech firms if drastic action isn’t taken
soon.
Genentech and Roche May Be Close to Deal
Roche raised their bid for the biotech last Friday to $93 dollars per share, luring Genentech back to
the negotiating table.
Wyeth V. Levine: An Attorneys’ Perspective
Lawyers from Duane Morris LLP offer their take on the Supreme Court’s groundshaking preemption
decision
Merck Takes Unusual Merger Tactic in Schering Deal
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some
eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep
Schering’s licensing deals secure. Was it the right move?
Podcast:Women of the Year-professor to president
Podcast:Women of the Year-professor to president. Anhal Purohit
Specialty Firms Shoot Down Big Money Bids
CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or
are they just not that into them?
